Drugs like Ozempic, Wegovy, and Zepbound are reshaping treatment for obesity and diabetes, and their benefits might extend further. Emerging research suggests that GLP-1 drugs could also help manage addiction, sleep apnea and even cancer.
These medications, which regulate hormones, slow digestion and reduce hunger, are showing promise in preventing cancers linked to obesity, such as breast, colon, liver, and ovarian cancers, according to research from the American Society of Clinical Oncology (ASCO).
Dr. Arif Kamal, the chief patient officers at the American Cancer Society, noted that GLP-1 drugs might significantly lower cancer risks and provide better protection for diabetics compared to insulin.
The ASCO research found that GLP-1 drugs could cut the risk of obesity-related cancers by 39%, compared to 22% with bariatric surgery over 10 years. Originally designed for diabetes, these drugs are now also approved for weight loss under names like Saxenda, Wegovy and Zepbound.
The link between obesity and cancer is complex, involving hormones like estrogen, which is elevated in fat cells and drives cancer growth. Kamal compared obesity’s impact on cancer to tobacco’s historical effect, emphasizing the significance of GLP-1 drugs in reducing cancer risk.
Cindy Lin, the co-author of the study, pointed out that GLP-1 drugs might offer protective effects beyond weight loss, including better glycemic control and anti-inflammatory benefits.
